BVS News and Press, Bioventus Inc.

2026-03-06 13:15:05 ET Craig-Hallum analyst issues BUY recommendation for BVS on March 6, 2026 02:55PM ET. The previous analyst recommendation was Buy. BVS was trading at $8.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2026-03-05 10:26:46 ET More on Bioventus Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript Bioventus Inc. 2025 Q4 - Results - Earnings Call Presentation Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Bioventus N...

2026-03-05 10:25:57 ET Bioventus Inc. (BVS) Q4 2025 Earnings Call March 5, 2026 8:30 AM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - Senior VP & ...

2026-03-05 09:48:41 ET Image source: The Motley Fool. Thursday, March 5, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-03-05 07:09:03 ET More on Bioventus Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Seeking Alpha’s Quant Rating on Bioven...

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 millio...

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...

DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the...

2026-02-09 08:04:24 ET from Barrington issued a price target of $13.00 for BVS on 2026-02-09 12:55:33. The adjusted price target was set to $13.00. At the time of the announcement, BVS was trading at $8.51. The overall price target consensus is at $9.83 with high price o...

2026-01-14 14:36:04 ET Bioventus Inc. (BVS) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 12:45 PM EST... Read the full article on Seeking Alpha For further details see: Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript